Amicus Financial Statements From 2010 to 2026

Amicus Therapeutics Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Assets 469.8 M 902.8 M 598.9 M Slightly volatile Other Assets 41.8 M 48.6 M 54.8 M Very volatile Common Stock Shares Outstanding 367.5 M 350 M 186.3 M Slightly volatile Liabilities And Stockholders Equity 491.9 M 902.8 M 600.2 M Slightly volatile Other Stockholder Equity 3.5 B 3.4 B 1.7 B Slightly volatile Total Liabilities 713.6 M 679.6 M 411.2 M Slightly volatile Other Current Liabilities 131.9 M 125.6 M 66.9 M Slightly volatile Total Current Liabilities 179.6 M 171 M 94.8 M Slightly volatile Accounts Payable 10.4 M 14.9 M 12.6 M Slightly volatile Cash 258.1 M 245.8 M 128.1 M Slightly volatile Short Term Investments 39.5 M 41.6 M 144.4 M Very volatile Other Current Assets 42.2 M 40.1 M 23.1 M Slightly volatile Common Stock 3.6 M 3.4 M 1.9 M Slightly volatile Property Plant Equipment 37.2 M 35.4 M 20.6 M Slightly volatile Short and Long Term Debt Total 535.7 M 510.2 M 246.6 M Slightly volatile Other Liabilities 20.2 M 21.3 M 75.2 M Pretty Stable Property Plant And Equipment Net 62.4 M 59.4 M 32.8 M Slightly volatile Non Current Assets Total 209.7 M 322.3 M 254.3 M Slightly volatile Non Currrent Assets Other 7.9 M 15.7 M 9.7 M Slightly volatile Cash And Short Term Investments 252.5 M 287.4 M 271.1 M Slightly volatile Common Stock Total Equity 3.4 M 3.2 M 1.9 M Slightly volatile Non Current Liabilities Total 255.5 M 508.6 M 303.3 M Slightly volatile Property Plant And Equipment Gross 97.1 M 92.5 M 42.4 M Slightly volatile Total Current Assets 306.8 M 580.4 M 349.1 M Slightly volatile Short Term Debt 5.9 M 9.7 M 6.9 M Pretty Stable Net Receivables 122.1 M 116.3 M 39.8 M Slightly volatile Capital Surpluse 1.7 B 3.1 B 1.6 B Slightly volatile Non Current Liabilities Other 6.1 M 6.4 M 87.7 M Slightly volatile Warrants 71 K 74.7 K 5.9 M Pretty Stable Long Term Debt Total 244.7 M 450.8 M 209.7 M Slightly volatile Long Term Investments 14 M 15.7 M 17.2 M Slightly volatile Short and Long Term Debt 100.3 M 189.1 M 107.1 M Slightly volatile Capital Lease Obligations 46.1 M 61.6 M 29.7 M Slightly volatile Net Invested Capital 482.7 M 525.7 M 556.2 M Pretty Stable Net Working Capital 303.5 M 320.4 M 347.8 M Pretty Stable Capital Stock 2.9 M 3.4 M 2.4 M Slightly volatile
Amicus Therapeutics Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Depreciation And Amortization 10.3 M 9.8 M 4.8 M Slightly volatile Other Operating Expenses 607.9 M 578.9 M 321.6 M Slightly volatile Research Development 120.4 M 125.8 M 144 M Slightly volatile Total Operating Expenses 543.9 M 518 M 300.3 M Slightly volatile Selling General Administrative 390.5 M 371.9 M 147.2 M Slightly volatile Cost Of Revenue 63.9 M 60.9 M 26.4 M Slightly volatile Interest Income 5.1 M 6.2 M 3.6 M Slightly volatile Reconciled Depreciation 6.7 M 9.8 M 5.3 M Slightly volatile Extraordinary Items 85.5 K 90 K 1.3 M Slightly volatile
Amicus Therapeutics Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Capital Expenditures 4.2 M 4.1 M 4.6 M Slightly volatile End Period Cash Flow 261.7 M 249.2 M 129.9 M Slightly volatile Begin Period Cash Flow 302 M 287.6 M 123.6 M Slightly volatile Depreciation 10.3 M 9.8 M 4.8 M Slightly volatile Stock Based Compensation 102.5 M 97.6 M 41.7 M Slightly volatile Change To Netincome 61.4 M 89.2 M 57.9 M Slightly volatile
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 5.93 6.24 80.2072 Slightly volatile Days Sales Outstanding 76.31 80.33 139 Slightly volatile Stock Based Compensation To Revenue 0.18 0.1607 1.9907 Slightly volatile Capex To Depreciation 0.45 0.48 1.4084 Slightly volatile EV To Sales 6.4 6.74 73.3276 Slightly volatile Inventory Turnover 0.49 0.51 0.7589 Slightly volatile Days Of Inventory On Hand 532 942 871 Slightly volatile Payables Turnover 2.98 4.7 3.5074 Slightly volatile Sales General And Administrative To Revenue 1.19 1.25 7.1653 Slightly volatile Research And Ddevelopement To Revenue 0.23 0.24 13.6356 Slightly volatile Capex To Revenue 0.0073 0.0077 0.3273 Slightly volatile Cash Per Share 0.9 0.94 5.0929 Slightly volatile Days Payables Outstanding 97.52 103 846 Pretty Stable Income Quality 1.08 0.69 0.7792 Slightly volatile Intangibles To Total Assets 0.37 0.31 0.3287 Very volatile Current Ratio 6.56 3.9 5.3439 Slightly volatile Receivables Turnover 3.58 4.7 4.3459 Slightly volatile Capex Per Share 0.0128 0.0134 0.4648 Slightly volatile Revenue Per Share 1.64 1.56 0.7239 Slightly volatile Interest Debt Per Share 0.9 1.46 1.1456 Slightly volatile Debt To Assets 0.53 0.51 0.3021 Slightly volatile Operating Cycle 419 800 634 Very volatile Days Of Payables Outstanding 97.52 103 846 Pretty Stable Long Term Debt To Capitalization 0.63 0.6 0.3708 Slightly volatile Quick Ratio 2.84 2.98 4.9554 Slightly volatile Net Income Per E B T 1.84 1.76 1.1143 Slightly volatile Cash Ratio 1.91 1.65 1.6885 Slightly volatile Days Of Inventory Outstanding 532 942 871 Slightly volatile Days Of Sales Outstanding 76.31 80.33 139 Slightly volatile Free Cash Flow Operating Cash Flow Ratio 1.16 1.27 1.0737 Slightly volatile Fixed Asset Turnover 9.66 9.2 4.6449 Slightly volatile Debt Ratio 0.53 0.51 0.3021 Slightly volatile Price Sales Ratio 5.93 6.24 80.2072 Slightly volatile Asset Turnover 0.64 0.61 0.2597 Slightly volatile
Amicus Therapeutics Valuation Data		Trends
Current Value Last Year Historical Average  10 Year Trend Market Cap 2.7 B 2.6 B 2 B Slightly volatile Enterprise Value 2.9 B 2.8 B 2.1 B Slightly volatile

Amicus Fundamental Market Drivers

Amicus Upcoming Events

About Amicus Therapeutics Financial Statements

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:

How To Invest In Amicus Details

Is Amicus Stock a good investment? Details

What is Amicus Therapeutics' Net Worth? Details

Largest Biotechnology Companies View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies View

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details